

December 4, 2012

Interprotein Corporation

Adoption of peptide VEGF inhibitor (micro antibody) program as a subject for A-STEP

Interprotein Corporation (President, Masato HOSODA; Headquarters: Osaka, Japan; hereinafter “Interprotein”) announced today that peptide VEGF inhibitor (micro antibody) program, which is now being conducted collaboratively by Professor Ikuo FUJII (Graduate School of Science, Osaka Prefecture University) and Interprotein, was adopted as a subject in the second approval (support type: Feasibility Study, Seeds Validation) of 2012 for A-STEP (Adaptable & Seamless Technology Transfer Program through Target-driven R&D) by Japan Science and Technology Agency (JST).

The subjects that were adopted in the second approval (Feasibility Study, Seeds Validation) of 2012 for A-STEP were listed in:

<http://www.jst.go.jp/a-step/kadai/h24-2fs.html> (in Japanese) or
<http://www.jst.go.jp/pr/info/info928/index.html> (in Japanese)

Contact:

Hirotsugu KOMATSU, Ph.D.

Interprotein Corporation

TEL/FAX: +81-(0)42-770-9477

E-mail : info@interprotein.com